1.
单药或联合方案治疗复发小细胞肺癌的前瞻性研究
Prospective studies of single-agent or combination chemotherapy for relapsed small cell lung cancer
| Regimen | n | Refractoy patients (%) | RR (%) | RR in refractory patients (%) | MST (month) |
| RR: response rate; MST: median survival time; NA: not available. | |||||
| Irinotecan | 15 | 7 | 47 | NA | 6.2 |
| Irinotecan | 31 | 64 | 0 | 0 | 4.6 |
| Paclitaxel | 24 | NA | 29 | NA | 3.3 |
| Picoplatin | 77 | 92 | 4 | NA | 5.2 |
| Belotecan | 25 | NA | 24 | NA | 9.9 |
| Cisplatin+Irinotecan | 24 | 64 | 80 | 81 | 7.9 |
| Etoposide+Irinotecan | 25 | 16 | 71 | 75 | 9.0 |
| Carboplatin+Paclitaxel | 34 | NA | 74 | NA | 7.2 |
| Carboplatin+Paclitaxel | 32 | 100 | 25 | 25 | 7.0 |